Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 64400141

Next Previous
Drug Profile

JNJ 64400141

Alternative Names: Ad26-RSV-preF; Ad26.RSV.preF; Ad26.RSV.preF-based vaccine; Adenovirus Serotype 26 (Ad26.RSV.preF)-based vaccine; JNJ-64400141; RSV Jr prophylactic vaccine - Janssen; RSV Senior prophylactic vaccine - Janssen; VAC-18193; VAC-18194

Latest Information Update: 27 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Vaccines and Prevention B.V
  • Class Respiratory syncytial virus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 16 May 2024 Janssen Vaccine and Prevention terminates the phase II CYPRESS trial in Respiratory syncytial virus infections (Prevention, In the elderly) in USA (IM), due to strategic reprioritization reasons (NCT03982199)
  • 03 Aug 2023 Janssen Vaccine and Prevention completes a phase II CYPRESS trial in Respiratory syncytial virus infections (Prevention, In the elderly) in USA (IM) (NCT03982199)
  • 17 May 2023 Janssen Pharmaceutical terminates a phase III trial in Respiratory syncytial virus infections (In the elderly, Prevention, In adults) in Japan (IM) due to sponsor's decision (NCT05242432)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top